content_image/144592.jpg content_image/144596.jpg content_image/144593.jpg
Despite a shifting landscape in the U.S., Canada and Latin America for the pharmaceutical industry and an ever more challenging business environment, we are continuing to grow a robust business in the Americas region and aggressively pursue opportunities that further reinforce our strength. This has been accomplished by ensuring best-in-class launches of our innovative therapies, including XTANDI and Myrbetriq, that serve the unmet needs of patients. In addition, we continue to ensure we maintain our leadership  positions throughout our portfolio. 

To accomplish this, we ensure that we prioritize investments appropriately, streamline our operations, improve our cost structure and focus on growth opportunities that contribute to the success of the organization. Finally, we continue to attract, develop and retain top talent in the industry to ensure we are well positioned for the future. We will continue to focus on the needs of patients, and ensure they are at the center of our priorities now and in the future. 

## Sales of Major Products 

<img src='content_image/144592.jpg'>

<img src='content_image/144596.jpg'>

* Forecast for the U.S. only 

<img src='content_image/144593.jpg'>

